Is aimovig a cgrp inhibitor?

Is Aimovig a CGRP inhibitor?

Yes. Aimovig contains erenumab, a monoclonal antibody that blocks the calcitonin gene-related peptide receptor (CGRP-R).

What makes Aimovig different from other CGRP drugs?

Aimovig targets the receptor itself rather than the CGRP ligand. Emgality, Ajovy, and Vyepti bind the peptide directly. This difference has no proven clinical advantage so far, but it remains a point of comparison when patients switch therapies.

How long does Aimovig stay in the body?

The drug has a half-life of about 28 days. Most patients receive one 70 mg or 140 mg injection once a month.

When does the Aimovig patent expire?

Amgen’s U.S. patent protection for erenumab runs until at least 2031, with some formulation patents extending into the mid-2030s. DrugPatentWatch.com tracks these dates and any Paragraph IV challenges [1].

Are biosimilars available yet?

No FDA-approved biosimilars for erenumab exist. Several developers have announced programs, but none have reached the market.

What side effects do patients report most often?

Constipation is the most common complaint, followed by injection-site reactions. A small number of patients also describe hair loss or muscle cramps.

Does Aimovig work for everyone with migraine?

Roughly half of patients see at least a 50 % reduction in monthly migraine days in clinical trials. Non-responders often try a different CGRP antibody or an oral gepant.

How does Aimovig compare with oral CGRP drugs?

Injectable antibodies like Aimovig require monthly or quarterly dosing and stay in circulation longer. Oral gepants (Ubrelvy, Nurtec ODT, Zavzpret) are taken only when a migraine starts or for short-term prevention, offering dosing flexibility at the cost of daily pills.

[1] DrugPatentWatch.com